摘要：The paper introduces the new challenges of benefit risk assessment of foods and drugs in modern personalized medicine. A new modeling of benefit -risk assessment with valued argumentation frameworks is presented and exemplified, and further research directions are suggested, as nutrigenomics will discover new bio-mechanisms relevant to nutrition and toxicity.
